New GSK diabetes drug works, but faces tough competition

June 24, 2013 10:36 AM

15 0

New GSK diabetes drug works, but faces tough competition

LONDON (Reuters) - GlaxoSmithKline's experimental once-weekly diabetes drug albiglutide was effective in late-stage clinical trials, but the medicine may struggle to differentiate itself in an increasingly competitive market.

Albiglutide belongs to the same class of injectable GLP-1 drugs as Victoza, from Novo Nordisk, and Byetta and Bydureon, from Bristol-Myers Squibb and AstraZeneca.

Read more

To category page

Loading...